Narita Miwako, Kuroha Takashi, Watanabe Norihiro, Hashimoto Shigeo, Tsuchiyama Junjiro, Tochiki Nozomi, Saitoh Anri, Satoh Noriyuki, Furukawa Tatsuo, Toba Ken, Fuse Ichiro, Aizawa Yoshifusa, Takahashi Masuhiro
Laboratory of Hematology and Oncology, Graduate School of Health Sciences, Niigata University, Niigata, Japan.
Acta Haematol. 2008;120(2):91-9. doi: 10.1159/000165510. Epub 2008 Oct 24.
We report 2 patients with plasmacytoid dendritic cell leukemia (pDCL) expressing CD4, CD56, CD33, CD36, HLA-DR, CD123, CD86 and CD83 in the absence of lineage markers (myeloid, B, T or natural killer cells) except for CD33. Culturing leukemic blasts of both cases with IL-3 for 4 days increased the expression of surface molecules associated with antigen presentation, e.g. CD1a and CD40. Leukemic blasts of both cases possessed a considerable level of antigen-presenting ability to allogeneic lymphocytes in mixed leukocyte cultures. Culturing the blasts with IL-3 for 4 days markedly increased allogeneic antigen presenting ability. Combined with data showing evident graft-versus-leukemia effects without graft-versus-host disease in a cord blood stem cell transplanted pDCL case, leukemic cells in pDCL may act as potent antigen presenting cells in vivo, too.
我们报告了2例浆细胞样树突状细胞白血病（pDCL）患者，其表达CD4、CD56、CD33、CD36、HLA-DR、CD123、CD86和CD83，除CD33外无谱系标志物（髓系、B细胞、T细胞或自然杀伤细胞）表达。将两例患者的白血病母细胞与白细胞介素-3（IL-3）培养4天，可增加与抗原呈递相关的表面分子的表达，如CD1a和CD40。两例患者的白血病母细胞在混合白细胞培养中对同种异体淋巴细胞具有相当水平的抗原呈递能力。将母细胞与IL-3培养4天可显著增强同种异体抗原呈递能力。结合脐血干细胞移植治疗pDCL病例时显示出明显的移植物抗白血病效应而无移植物抗宿主病的数据，pDCL中的白血病细胞在体内也可能作为有效的抗原呈递细胞。
